Both in Biotechnology
Beam Therapeutics vs ADMA Biologics
Over the past year BEAM returned +2.6% and ADMA returned −32.2%; their daily moves had a correlation of 0.22.
BEAM +2.6% ADMA −32.2%Growth of $1, one year, split-adjusted
| Metric | BEAM | ADMA |
|---|---|---|
| Price | $24.52 | $9.96 |
| Market cap | $2.53B | $2.23B |
| Today | +1.20% | −1.58% |
| 1 month | −16.4% | +6.6% |
| 6 months | +12.0% | +8.9% |
| Year to date | −11.5% | −45.4% |
| 1 year | +6.7% | −36.2% |
| Revenue growth (YoY) | −94.2% | +2.0% |
| Gross margin | 100.0% | 69.4% |
| Net margin | −25036.3% | 30.4% |
| P/E (TTM) | — | 13.2× |
| Price / sales | 16.2× | 4.4× |
| Net cash | $1.05B | -$60.6M |
| Dividend yield | — | — |
| Volatility (60d) | 63.4% | 40.6% |
| Short % of float | 31.6% | 11.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).